Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1641 1643 1644
This examiner grants 66% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18499720 | BCMA-TARGETED CAR-T CELL THERAPY OF MULTIPLE MYELOMA | Non-Final OA | JANSSEN BIOTECH, INC. |
| 18210604 | ASSEMBLY OF BISPECIFIC ANTIBODIES | Final Rejection | Genentech, Inc. |
| 16852136 | HINGE MODIFIED ANTIBODY FRAGMENTS AND METHODS OF MAKING | Final Rejection | GENENTECH, INC. |
| 17628418 | COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE DISORDERS | Non-Final OA | The Regents of the University of Michigan |
| 18509030 | COMPOSITIONS AND METHODS FOR FIBROBLAST GROWTH FACTOR RECEPTOR 3-MEDIATED DELIVERY TO ASTROCYTES | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18570723 | TARGETED ADAM17 BLOCKER COMPOUNDS, ANTI-ADAM17 ANTIBODIES, METHODS OF MAKING, AND METHODS OF USING | Non-Final OA | REGENTS OF THE UNIVERSITY OF MINNESOTA |
| 18282503 | CHIMERIC PHAGOCYTIC RECEPTORS FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | Non-Final OA | University of Florida Research Foundation, Incorporated |
| 18256916 | HUMAN CHIMERIC ANTIGEN RECEPTOR NEUTROPHILS, COMPOSITIONS, KITS AND METHODS OF USE | Non-Final OA | Purdue Research Foundation |
| 17771227 | COMBINED INHIBITION OF PD-1, TGFB AND TIGIT FOR THE TREATMENT OF CANCER | Non-Final OA | MERCK PATENT GmbH |
| 18182093 | ANTIBODY DRUG CONJUGATES (ADCS) HAVING ENZYMATICALLY CLEAVABLE GROUPS | Final Rejection | Bayer Aktiengesellschaft |
| 18463047 | HYPERGLYCOSYLATED BINDING POLYPEPTIDES | Non-Final OA | GENZYME CORPORATION |
| 18185465 | PSEUDOFAB-BASED MULTISPECIFIC BINDING PROTEINS | Final Rejection | SANOFI |
| 18430887 | METHOD FOR DETERMINING THE AMOUNT OF A THERAPEUTIC ANTIBODY IN THE BRAIN | Non-Final OA | Hoffmann-La Roche Inc. |
| 17507511 | ACTIVATABLE THERAPEUTIC MULTISPECIFIC POLYPEPTIDES WITH EXTENDED HALF-LIFE | Final Rejection | Hoffmann-La Roche Inc. |
| 18028420 | THERAPEUTIC USE, FOR NEURODEGENERATIVE DISEASES, OF TRIPLE AGONIST HAVING ACTIVITY WITH RESPECT TO ALL OF GLUCAGON, GLP-1, AND GIP RECEPTORS, OR CONJUGATE THEREOF | Final Rejection | HANMI PHARM. CO., LTD. |
| 17931258 | BISPECIFIC CAR T-CELLS FOR SOLID TUMOR TARGETING | Final Rejection | Seattle Children's Hospital (dba Seattle Children's Research Institute) |
| 18251006 | USE OF ANTI-TREM1 NEUTRALIZING ANTIBODIES FOR THE TREATMENT OF MOTOR NEURON NEURODEGENERATIVE DISORDERS | Final Rejection | UCB BIOPHARMA SRL |
| 18612960 | Bispecific Asymmetric Heterodimers Comprising Anti-CD3 Constructs | Final Rejection | ZYMEWORKS BC INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy